Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Ipca Laboratories Limited

Market Cap 409B 4.28B 3.71B 3.42B 3.2B 5.99B 6.11B 40.8B 15.8B 197B 16.05B 15.7B 686B P/E Ratio 2026
35.6x
P/E Ratio 2027 * 29.3x
Enterprise Value 404B 4.22B 3.66B 3.38B 3.17B 5.91B 6.04B 40.3B 15.6B 195B 15.85B 15.51B 678B EV / Sales 2026
4.24x
EV / Sales 2027 * 3.64x
Free-Float
54.92%
Yield 2026
0.37%
Yield 2027 * 0.36%
1 day-0.85%
1 week-2.56%
Current month+4.95%
1 month+6.02%
3 months+2.51%
6 months+9.14%
Current year+12.76%
1 week 1,596.1
Extreme 1596.1
1,670
1 month 1,470
Extreme 1470
1,678.3
Current year 1,391.8
Extreme 1391.8
1,678.3
1 year 1,251.6
Extreme 1251.6
1,678.3
3 years 691.2
Extreme 691.2
1,755.9
5 years 669.8
Extreme 669.8
1,755.9
10 years 200
Extreme 200
1,755.9
Manager TitleAgeSince
Chief Executive Officer 53 2023-03-31
Chief Executive Officer 70 2023-03-31
Chief Tech/Sci/R&D Officer 52 2023-10-15
Director TitleAgeSince
Chairman 79 2012-07-04
Director/Board Member 53 2008-11-10
Director/Board Member 70 1994-07-31
Date Insider Type Main position Quantity % Market Cap.
24-12-18Sell 4,000,000 1.5766%
Change 5-day change 1-year change 3-year change Capi.($)
-0.94%-2.56%+15.68%+119.00% 4.28B
+2.16%+3.17%+43.57%+160.28% 1,035B
-0.07%+4.45%+53.50%+48.95% 574B
-0.08%-0.08%+17.37%+62.66% 397B
+0.77%+0.77%+21.19%+15.95% 324B
+0.85%+0.18%+24.50%+15.93% 281B
+2.10%+4.92%+25.30%+34.79% 278B
-0.19%-0.46%-45.32%-48.23% 193B
+4.84%+2.45%+21.33%+61.85% 191B
+3.61%-2.56%+15.16%+61.12% 156B
Average +1.31%+1.51%+19.23%+53.23% 343.42B
Weighted average by Cap. +1.36%+2.39%+29.49%+73.03%

Financials

2026 2027 *
Net sales 96.62B 1.01B 876M 807M 756M 1.41B 1.44B 9.63B 3.73B 46.57B 3.79B 3.71B 162B 108B 1.12B 976M 900M 843M 1.58B 1.61B 10.73B 4.16B 51.92B 4.22B 4.13B 181B
Net income 11.21B 117M 102M 93.63M 87.73M 164M 167M 1.12B 432M 5.4B 439M 430M 18.78B 14.04B 147M 127M 117M 110M 205M 210M 1.4B 542M 6.77B 550M 538M 23.53B
Net Debt -5.02B -52.4M -45.47M -41.91M -39.27M -73.38M -74.91M -500M -194M -2.42B -197M -192M -8.41B -17.17B -179M -156M -143M -134M -251M -256M -1.71B -662M -8.28B -673M -659M -28.78B
Logo Ipca Laboratories Limited
Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The Company’s products are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc. and Ipca Pharma Nigeria Ltd.
Employees
16,778
Date Price Change Volume
26-06-12 1,598.50 -0.94% 54,746
26-06-11 1,613.60 -1.02% 86,082
26-06-10 1,630.20 -0.23% 172,179
26-06-09 1,634.00 -0.93% 116,776
26-06-08 1,649.40 +0.46% 924,718
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
1,613.60INR
Average target price
1,719.61INR
Spread / Average Target
+6.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IPCALAB Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!